LY2140023 has the potential for schizophrenia.LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2/3 receptor agonist.

LY2140023 (orally;?3, 10, and 300 mg/kg;?once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid and homovanillic acid (HVA)[1].

635318-55-7

C12H18N2O7S2

366.41

LY2140023

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years